Navigation Links
ImQuest Presents New Anti-HIV Drug and Topical Microbicide Development Results on Lead Pyrimidinedione Products IQP-0410 and IQP-0528
Date:4/16/2008

FREDERICK, Md., April 16 /PRNewswire/ -- ImQuest Life Sciences today presented important new results on the development of their lead anti-HIV therapeutic development candidate, IQP-0410, and lead topical microbicide development candidate, IQP-0528. ImQuest scientists Robert W. Buckheit, Jr., Ph.D. (Executive Vice President and Chief Scientific Officer) and Karen M. Watson, M.S. (Manager, Topical Microbicide Research & Development) were invited to speak at The International Conference on Antiviral Research (ICAR), being held this week in Montreal, Quebec, Canada. ImQuest studies have demonstrated that each of these highly novel pyrimidinedione inhibitors act by two distinct mechanisms of action, preventing the entry of HIV into human cells and inhibiting the activity of a key HIV enzyme, reverse transcriptase.

Dr. Buckheit presented detailed mechanism of action evaluations performed with IQP-0410, demonstrating that the compound targets a newly defined conformational cell surface target formed upon attachment of the virus to prevent the entry of HIV into the cells. This molecular target will be exploited by ImQuest to develop even more potent HIV entry inhibitors. Ms. Watson reported on results of preclinical efficacy and safety testing on the related pyrimidinedione microbicide, IQP-0528, to prevent the sexual transmission of HIV worldwide. The ImQuest team also demonstrated that IQP- 0410 was highly effective against multi-drug resistant HIV, especially viruses derived from patients treated extensively with protease inhibitors. The studies included ImQuest co-authors Lu Yang, M.D., Tracy Hartman, M.S., Christa E. Buckheit and Robert W. Buckheit, III.

"Our results clearly indicate that the pyrimidinediones represent a completely new class of HIV inhibitor that may be of great benefit to the prevention of HIV infection as a topical microbicide, the therapeutic treatment of primary HIV infection, as well as a salvage therapy for patients failing current drug regimens," said Dr. Buckheit. "We are excited that these molecules are rapidly progressing towards human clinical trials."

ImQuest Life Sciences, a privately held U.S. company located in Frederick, Maryland specializes in the preclinical and clinical development of novel compounds for the treatment of infectious disease and cancer. ImQuest BioSciences, also located in Frederick, Maryland, is a leading provider of anti-infective and anti-cancer drug and vaccine development services to the biotechnology and pharmaceutical industry.

For further information regarding this press release please contact:

Robert W. Buckheit, Jr., Ph.D.

Executive Vice President and Chief Scientific Officer

ImQuest Life Sciences, Inc.

301-696-0274

rbuckheit@imquest.com


'/>"/>
SOURCE ImQuest Life Sciences
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Sunesis Pharmaceuticals Presents Nonclinical Data on SNS-595 at the Annual Meeting of the American Association for Cancer Research
2. NovoCure presents results from breast cancer pilot study
3. Center for Connected Health Presents Growing Evidence of the Benefits of Technology to Improve Patient Satisfaction and Empowerment
4. Gourmetceuticals Presents Findings on Science You Can Eat at Experimental Biology 2008
5. 5W Public Relations Presents the 2008 Body Beautiful Media Symposium Benefiting The Skin Cancer Foundation
6. CVS Caremark Presents at NCOA-ASA Conference on Companys Commitment to Recruiting and Retaining Mature Workers
7. RNR Public Relations Presents Perfect April Fools Day Feature Opportunity
8. New Jersey Hospital Association Presents Awards for Commitment to Healthcare
9. Brain stress system presents possible treatment
10. Joanne Steen Presents Grief Solutions at the Headquarters Marine Corps 2008 Casualty Conference
11. QueensLander Tours Presents an Adventure Boot Camp Cruise with John Spencer Ellis from Bravos The Real Housewives of Orange County
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... June 26, 2016 , ... Brent Kasmer, a legally blind and certified personal trainer is helping ... fitness app. The fitness app plans to fix the two major problems leading the fitness ... size fits all type program , They don’t eliminate all the reasons people ...
(Date:6/25/2016)... , ... June 25, 2016 , ... The temporary closing of Bruton Memorial Library on ... Observer , brings up a new, often overlooked aspect of head lice: the parasite’s ability ... fumigation is not a common occurrence, but a necessary one in the event that lice ...
(Date:6/25/2016)... ... June 25, 2016 , ... ... non-athletes recover from injury. Recently, he has implemented orthobiologic procedures as a method ... —Johnson is one of the first doctors to perform the treatment. Orthobiologics are ...
(Date:6/24/2016)... ... ... Those who have experienced traumatic events may suffer from a complex set ... drug or alcohol abuse, as a coping mechanism. To avoid this pain and suffering, ... traumatic event. , Trauma sufferers tend to feel a range of emotions, from depression, ...
(Date:6/24/2016)... ... June 24, 2016 , ... Global law firm Greenberg Traurig, ... Elite. The attorneys chosen by their peers for this recognition are considered among the ... Traurig Shareholders received special honors as members of this year’s Legal Elite Hall of ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... , June 27, 2016  VMS Rehab Systems, Inc. ... will take whatever measures required to build a strong ... which is currently listed on the OTC Markets-pink current ... Chairman and CEO, "We are seeing an anomaly in ... understand, not only by the Company, but shareholders and ...
(Date:6/24/2016)... 24, 2016   Bay Area Lyme Foundation ... Dean Center for Tick Borne Illness , Harvard ... MIT Hacking Medicine, University of California, Berkeley, and ... the five finalists of Lyme Innovation , ... than 100 scientists, clinicians, researchers, entrepreneurs, and investors ...
(Date:6/24/2016)... and SAN CLEMENTE, Calif. , June 24, 2016 ... mobile pulmonary function testing company, is now able to perform sophisticated ... by ndd Medical Technologies , Inc. Patients ... hospital-based labs.  Thanks to ndd,s EasyOne PRO ® , ARL patients ... get any needed testing done in the comfort of her own ...
Breaking Medicine Technology: